Zalypsis potentiates the antimyeloma action of conventional and novel antimyeloma agents. MM1S cells were treated for 72 hours with suboptimal concentrations of Zalypsis and other antimyeloma agents, such as dexamethasone, melphalan, doxorubicin, bortezomib, and lenalidomide in double (A) and triple combinations (B). Cell viability was analyzed by MTT assay.